We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
GSK2374697, a long duration glucagon-like peptide-1 ( GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.
- Authors
Lin, J.; Hodge, R. J.; O'Connor‐Semmes, R. L.; Nunez, D. J.
- Abstract
We investigated the effects of a long-duration glucagon-like peptide-1 ( GLP-1) receptor agonist, GSK2374697, on postprandial endogenous total GLP-1 and peptide YY ( PYY). Two cohorts of healthy subjects, one normal/overweight and one obese, were randomized to receive GSK2374697 2 mg (n = 8 each) or placebo (n = 4 and n = 2) subcutaneously on days 1, 4 and 7. Samples for plasma endogenous GLP-1 and PYY were collected after breakfast on days −1 and 12. Weighted mean area under the curve (0-4 h) of total GLP-1 and PYY in treated subjects was reduced compared with placebo. The least squares mean difference for change from baseline was −1.24 pmol/l [95% confidence interval ( CI) −2.33, −0.16] and −4.47 pmol/l (95% CI −8.74, −0.20) for total GLP-1 and PYY, respectively, in normal/overweight subjects (p < 0.05 for both), and −1.56 (95% CI −2.95, −0.16) and −3.02 (95% CI −8.58, 2.55), respectively, in obese subjects (p < 0.05 for GLP-1). In healthy subjects, GSK2374697 reduced postprandial total GLP-1 and PYY levels, suggesting feedback suppression of enteroendocrine L-cell secretion of these peptides.
- Subjects
GLUCAGON-like peptide-1 agonists; PEPTIDE YY; PLACEBOS; OVERWEIGHT persons; LEAST squares; CONFIDENCE intervals
- Publication
Diabetes, Obesity & Metabolism, 2015, Vol 17, Issue 10, p1007
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.12533